MIRA INFORM REPORT

 

 

Report No. :

344874

Report Date :

12.10.2015

 

                                                                IDENTIFICATION DETAILS

 

Name :

GLAND PHARMA LIMITED (w.e.f. 05.12.1994)

 

 

Formerly Known As :

GLAND PHARMA PRIVATE LIMITED

 

 

Registered Office :

6-3-865/1/2, Flat No. 201, Greenland Apartments, Ameerpet, Hyderabad - 500016, Telangana

Tel No.:

91-40-23541535

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

20.03.1978

 

 

Com. Reg. No.:

36-002276

 

 

Capital Investment / Paid-up Capital :

Rs.117.585 Million

 

 

CIN No.:

[Company Identification No.]

U24239AP1978PLC002276

 

 

IEC No.:

0990002110

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

HYDG00199D

 

 

PAN No.:

[Permanent Account No.]

AAACG8036B

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Subject is engaged in the business of pharmaceutical production and marketing, including manufacturer and sale of specialized injectable, active pharmaceutical ingredients (APIs) and formulations for generics versions of drugs.    

 

 

No. of Employees :

Information declined by the management

 

 

                                                                  RATING & COMMENTS

 

MIRA’s Rating :

A (68)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavorable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 23819000

 

 

Status :

Good

 

 

Payment Behavior :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject was incorporated in the year 1978 and it is engaged in manufacturing pharmaceuticals ingredients.

 

For the financial year ended 2014, company has reported 31.46% sales turnover growth as compared to previous sales turnover and it has maintained decent profitability margins at 22.59% during the year under a review.

 

The rating also reflects company's healthy financial profile marked by adequate net worth base along with sound debt protection indicators and favorable liquidity position of the company.

 

Trade relations are reported as fair. Payments are reported to be regular and as per commitment.

 

The company can be considered good for normal business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

                                                             EXTERNAL AGENCY RATING

 

Rating Agency Name

FITCH

Rating

Long term issuer rating : A+

Rating Explanation

Adequate degree of safety and low credit risk.

Date

04.08.2014

 

 

                                                          RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2015.

 

                                                                INFORMATION DECLINED

 

MANAGEMENT NON-COOPERATIVE

 

Contact No: (91-40-66621010)

 

 

 

                                                                           LOCATIONS

 

Registered Office :

6-3-865/1/2, Flat No. 201, Green Land Apartments, Ameerpet, Hyderabad - 500016, Telangana, India

Tel. No.:

91-40-23541535 / 66621010

Fax No.:

91-40-23402229

E-Mail :

sampath@glandpharma.com

gland@hd1.vsnl.net.in

gland@glandpharma.com

yvgkrao@glandpharma.com

Website :

http://www.glandpharma.com

Area :

4000 Sq .ft

Location :

Owned

 

 

Factory 1 :

Plot No. 9, Anrich Industrial Estate, Bollaram, Hyderabad - 502325, Telangana,

India

 

 

Factory 2:

D. P. Pally Village, Dunogial P.O. Hyderabad-500016, Telangana,  India

 

 

Factory 3:

Plot No. C1-C9, Visakhapatnam Special Economic Zone (VSEZ), Duvvada, Visakhapatnam- 530046, Andhra Pradesh, India

 

 

Branch Office:

Near Ghandi Maisamma “X” Roads, D. P. Pally, Hyderabad - 500043, Telangana,  India

 

 

                                                                           DIRECTORS

 

As on 29.09.2014

 

Name :

Mr. Penmetsa Venkata Narasimha Raju

Designation :

Whole-time director

Address :

6-3-865/1/A/303, Green Land Apartments, Ameerpet, Hyderabad - 500016, Telangana, India

Date of Birth/Age :

28.05.1933

Date of Appointment :

01.10.2009

DIN No.:

00180021

PAN No.:

AFIPP8042G

 

 

Name :

Mr. Ravindranath Penmesta

Designation :

Managing Director

Address :

6-3-865/1/A/303, Green Land Apartments, Ameerpet, Hyderabad - 500016, Telangana, India

Date of Birth/Age :

11.10.1956

Date of Appointment :

01.10.2009

DIN No.:

00179939

PAN No.:

AHMPP1651R

 

 

Name :

Mr. Mohammed Moheb Masthan Ali

Designation :

Director

Address :

8-2-676/B/12, Plot No.48, Sai Nagar Colony, Banjara Hills,  Road No. 13, Hyderabad- 500034, Telangana,  India.

Date of Birth/Age :

12.12.1943

Date of Appointment :

29.09.2006

DIN No.:

00699254

 

 

Name :

Mr. Udo Jahannes Vetter

Designation :

Director

Address :

Banneggstrabe 57, Ravenburg 88214, Germany

Date of Birth/Age :

23.11.1954

Date of Appointment :

22.12.2007

DIN No.:

00707474

 

 

Name :

Mr. Sanjay Omprakash Nayar

Designation :

Nominee Director

Address :

Flat No. 9, The Rushilla Cooperative Housing Society Limited, 17/C, Carmicael Road, Mumbai – 400026, Maharashtra, India

Date of Birth/Age :

13.10.1960

Date of Appointment :

17.06.2014

DIN No.:

00002615

 

 

Name :

Mr. Karan Singh Swani

Designation :

Nominee Director

Address :

28A, Belvedere Court Building, Modern Mills, Compound Sane, Guruji Marg, Mahalaxmi, Mumbai – 400011, Maharashtra India

Date of Birth/Age :

04.08.1980

Date of Appointment :

17.06.2014

DIN No.:

06898342

 

 

Name :

Mr. Davinder Singh Brar

Designation :

Director

Address :

Green Fields Farm, Gadaipur, Jaunapur Road, Village – Gadaipur, Tehsil Mehrauli, New Delhi – 110030, India

Date of Birth/Age :

21.08.1952

Date of Appointment :

17.06.2014

DIN No.:

00068502

 

 

Name :

Mr. Narasimha Rao Bandreddi

Designation :

Whole-time Director

Address :

7-1-48/5/3, Flat No. 401, Sai Madhavi, Enclave, Raja Sham Karam Road, Ameerpet, Hyderabad – 500016, Telangana, India

Date of Birth/Age :

01.01.1958

Date of Appointment :

17.06.2014

DIN No.:

00071116

 

 

Name :

Mr. Srinivas Sadu

Designation :

Whole-time Director

Address :

MIG -31, APIIC Colony, Moula Ali, Hyderabad – 500040, Telangana, India

Date of Birth/Age :

15.04.1969

Date of Appointment :

17.06.2014

DIN No.:

06900659

 

 

Name :

Kalidindi Jhansi Lakshmi

Designation :

Additional Director

Address :

Flat No.301, H.No. 6-3-865, My Home Gardenia Apartment, Ameerpet, Hyderabad - 500016, Telangana, India

Date of Appointment :

04.08.2015

DIN No.:

01197993

 

 

                                                                      KEY EXECUTIVES

 

Name :

Mr. Sampath Kumar Pallerlamudi

Designation :

Secretary

Address :

Flat No.102, Venus Residency, Motinagar, Near E-Seva,., Hyderabad - 500018, Telangana, India

Date of Appointment :

17.12.2013

PAN No.:

ALTPP1482D

 

 

MAJOR SHAREHOLDERS

 

AS ON 29.09.2014

 

SHAREHOLDING DETAILS FILE ATTACHED

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 29.09.2014

 

Category

Percentage

Foreign holdings( Foreign institutional investor(s), Foreign companies (s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

52.15

Bodies corporate

45.69

Directors or relatives of Directors

2.16

Total

100.00

 

 

 

 

BUSINESS DETAILS

 

Line of Business :

Subject is engaged in the business of pharmaceutical production and marketing, including manufacturer and sale of specialized injectable, active pharmaceutical ingredients (APIs) and formulations for generics versions of drugs.    

 

 

Products :

 

ITEM CODE NO

PRODUCT DESCRIPTION

30019091

Enoxaparin

30019091

Heparin

30019099

Choindroitin Sulfate

29420001

Protamine Sulphate

29420039

Amikacin

29420039

Sodium Hyaluronate

30019099

Glucosamine

 

 

Brand Names :

Not Divulged

 

 

Agencies Held :

Not Divulged

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

Not Divulged

 

PRODUCTION STATUS: NOT AVAILABLE

 

 

                                                                GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

Customers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

No. of Employees :

Information declined by the management

 

 

Bankers :

  • Syndicate Bank, Corporate Finance Branch, Somajiguda, Hyderabad - 500082, Telangana, India
  • The Bank of Nova Scotia, 6-3-346/1, Road No 1, Banjarahills, Hyderabad - 500034, Telangana, India

 

 

Facilities :

Secured Loan

31.03.2014

(Rs. in Million)

31.03.2013

(Rs. in Million)

Long-term Borrowings

 

 

Rupee term loans from banks

850.000

300.000

Other loans and advances, others

3.563

7.204

Short-term borrowings

 

 

Rupee term loans from banks

482.080

436.800

Other loans and advances, others

100.565

413.644

Total

1436.208

1157.648

 

 

 

Banking Relations :

--

 

 

Auditors 1 :

 

Name :

Y. Raghuram and Company

Chartered Accountants

Address :

118, Phase –I, Kamalapuri, 8-3-833/ 118, Srinagar Colony, Hyderabad - 500073, Telangana, India

PAN N Income-tax PAN of auditor or auditor's firm :

AAAFY5141J

 

 

Auditors :

 

Name :

S.R.batliboi and associates LLP

Chartered Accountants

Address :

The Oval Office, 18 ILABS Centre, Madhapur, Hyderabad 500081, Telangana, India

PAN N Income-tax PAN of auditor or auditor's firm :

ACHFS9118A

 

 

Memberships :

--

 

 

Collaborators :

--

 

 

Enterprises which are

owned, or have significant

influence of or are partners

with Key management

personnel and their relatives :

Gland Chemicals Private Limited (U24110AP1974PTC001694)

 

 

 

CAPITAL STRUCTURE

 

As on 29.09.2014

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

18000000

Equity Shares

Rs.10/- each

Rs.180.000 Million

6300000

Preference Shares

Rs.10/- each

Rs.63.000 Million

 

Total

 

Rs. 243.000 Million

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

15672449

Equity Shares

Rs.10/- each

Rs.156.724 Million

 

As on 31.03.2014

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

16000000

Equity Shares

Rs.10/- each

Rs.160.000 Million

1000000

Preference Shares

Rs.10/- each

Rs.10.000 Million

 

Total

 

Rs. 170.000 Million

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

11758494

Equity Shares

Rs.10/- each

Rs.117.585 Million

 

 

FINANCIAL DATA

[all figures are in Rupees Million]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

31.03.2014

31.03.2013

31.03.2012

 

 

 

 

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

117.585

117.585

117.585

(b) Reserves & Surplus

8218.921

5980.129

4399.213

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

8336.506

6097.714

4516.798

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

922.924

377.691

93.812

(b) Deferred tax liabilities (Net)

393.219

233.384

197.434

(c) Other long term liabilities

2.650

2.650

7.650

(d) long-term provisions

4.088

10.903

5.373

Total Non-current Liabilities (3)

1322.881

624.628

304.269

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

582.645

850.444

750.784

(b) Trade payables

984.749

557.852

536.476

(c) Other current liabilities

1629.949

1027.654

1047.033

(d) Short-term provisions

9.242

42.132

25.014

Total Current Liabilities (4)

3206.585

2478.082

2359.307

 

 

 

 

TOTAL

12865.972

9200.424

7180.374

 

 

 

 

II.          ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

4597.441

3085.640

2062.026

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

2078.770

2020.195

1427.455

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.525

0.525

0.275

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

215.120

99.011

25.992

(e) Other Non-current assets

3.468

3.468

0.000

Total Non-Current Assets

6895.324

5208.839

3515.748

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

3063.594

1676.489

1804.611

(c) Trade receivables

1682.013

1279.139

920.843

(d) Cash and cash equivalents

771.039

913.064

840.684

(e) Short-term loans and advances

265.718

118.181

90.531

(f) Other current assets

188.284

4.712

7.957

Total Current Assets

5970.648

3991.585

3664.626

 

 

 

 

TOTAL

12865.972

9200.424

7180.374

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

Income

9909.206

7553.450

5266.697

 

Other Income

85.351

48.879

138.849

 

TOTAL

9994.557

7602.329

5405.546

 

 

 

 

 

Less

EXPENSES

 

 

 

 

Cost of Materials Consumed

4300.663

3577.661

2797.205

 

Purchases of Stock-in-Trade

123.854

93.742

65.299

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(299.945)

(52.880)

3.107

 

Employees benefits expense

814.354

659.9

460.023

 

Other expenses

1364.188

913.956

610.155

 

TOTAL

6303.114

5192.379

3935.789

 

 

 

 

 

Less

PROFIT/ (LOSS)  BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

3691.443

2409.950

1469.757

 

 

 

 

 

Less

FINANCIAL EXPENSES

133.759

129.570

27.691

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

3557.684

2280.380

1442.066

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION

284.235

145.658

108.207

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

3273.449

2134.722

1333.859

 

 

 

 

 

Less

TAX

1034.657

553.806

321.591

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX 

2238.792

1580.916

1012.268

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD 

4762.641

3183.725

2173.457

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

Transfer to General Reserve

NA

2.000

2.000

 

Balance Carried to the B/S

NA

4762.641

3183.725

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

NA

NA

3848.179

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

190.40

134.45

86.09

 

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

Particulars

 

31.03.2014

31.03.2013

31.03.2012

Current Maturities of Long term debt

256.284

6.983

73.924

Cash generated from operations

NA

NA

NA

Net cash flows from (used in) operations

2144.941

1832.217

1482.589

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Net Profit Margin

(PAT / Sales)

(%)

22.59

20.93

19.22

 

 

 

 

 

Operating Profit Margin

(PBIDT/Sales)

(%)

37.25

31.91

27.91

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

30.35

29.73

23.19

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.39

0.35

0.30

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.21

0.20

0.20

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.86

1.61

1.55

 


 

FINANCIAL ANALYSIS

[all figures are in Rupees Million]

 

DEBT EQUITY RATIO                

 

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Share Capital

117.585

117.585

117.585

Reserves & Surplus

4399.213

5980.129

8218.921

Money received against share warrants

0.000

0.000

0.000

 Share Application money pending allotment

0.000

0.000

0.000

Net worth

4516.798

6097.714

8336.506

 

 

 

 

long-term borrowings

93.812

377.691

922.924

Short term borrowings

750.784

850.444

582.645

Current maturities of long-term debts

73.924

6.983

256.284

Total borrowings

918.520

1235.118

1761.853

Debt/Equity ratio

0.203

0.203

0.211

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

5266.697

7553.450

9909.206

 

 

43.419

31.188

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Sales

5266.697

7553.450

9909.206

Profit

1012.268

1580.916

2238.792

 

19.22%

20.93%

22.59%

 

 


 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check list by info agents

Available in Report (Yes/No)

1

Year of establishment

Yes

2

Constitution of the entity -Incorporation details

Yes

3

Locality of the entity

Yes

4

Premises details

No

5

Buyer visit details

--

6

Contact numbers

Yes

7

Name of the person contacted

No

8

Designation of contact person

No

9

Promoter’s background

Yes

10

Date of Birth of Proprietor / Partners / Directors

Yes

11

Pan Card No. of Proprietor / Partners

No

12

Voter Id Card No. of Proprietor / Partners

No

13

Type of business

Yes

14

Line of Business

Yes

15

Export/import details (if applicable)

Yes

16

No. of employees

No

17

Details of sister concerns

Yes

18

Major suppliers

No

19

Major customers

No

20

Banking Details

Yes

21

Banking facility details

Yes

22

Conduct of the banking account

--

23

Financials, if provided

Yes

24

Capital in the business

Yes

25

Last accounts filed at ROC, if applicable

Yes

26

Turnover of firm for last three years

Yes

27

Reasons for variation <> 20%

--

28

Estimation for coming financial year

No

29

Profitability for last three years

Yes

30

Major shareholders, if available

Yes

31

External Agency Rating, if available

Yes

32

Litigations that the firm/promoter involved in

--

33

Market information

--

34

Payments terms

No

35

Negative Reporting by Auditors in the Annual Report

No

 


 

UNSECURED LOAN

 

PARTICULARS

31.03.2014

(Rs. in Million)

31.03.2013

(Rs. in Million)

Long-term Borrowings

 

 

Deferred sales tax loan

69.361

70.487

Total

69.361

70.487

 

INDEX OF CHARGES

 

S.NO.

CHARGE ID

DATE OF CHARGE CREATION/MODIFICATION

CHARGE AMOUNT SECURED

CHARGE HOLDER

ADDRESS

SERVICE REQUEST NUMBER (SRN)

1

10378069

31/01/2013 *

1,000,000,000.00

ICICI BANK LIMITED

ICICI BANK TOWERS, PLOT NO.12, GACHIBOWLI, HYDERA
BAD, ANDHRA PRADESH - 500032, INDIA

B68366657

2

10364728

14/09/2012 *

1,000,000,000.00

SYNDICATE BANK

CORPORATE FINANCE BRANCH, 6-3-666, FIRST FLOOR, L
UMBINI TOWERS, SOMAJIGUDA, HYDERABAD, ANDHRA PRADE
SH - 500082, INDIA

B60102928

3

80010582

11/01/2014 *

1,400,000,000.00

THE BANK OF NOVA SCOTIA

6-3-346/1, ROAD NO 1, BANJARAHILLS, HYDERABAD, AN
DHRA PRADESH - 500034, INDIA

B94861333

4

80010646

26/03/2013 *

1,800,000,000.00

SYNDICATE BANK

CORPORATE FINANCE BRANCH, 6-3-666, FIRST FLOOR, L
UMBINI TOWERS, SOMAJIGUDA, HYDERABAD, ANDHRA PRADE
SH - 500082, INDIA

B73576241

 

* Date of charge modification

 

 

 

CONTINGENT LIABILITIES:

 

(Rs. in Million)

PARTICULARS

31.03.2014

31.03.2013

 

 

 

Outstanding bank guarantees

43.929

43.583

Indirect tax cases against the Company

10.128

10.128

Claims against the Company not acknowledged as debts

23.048

3.895

The Company entered into a Secondary manufacturing agreement (agreement) dated April 19, 2002 with Genemedix PLC (Genemedix). As part of the agreement, Genemedix was required to install Lyophilzer in Company’s factory and provide Company with raw material for performing secondary manufacturing. In 2002, Genemedix installed the asset, however, since, did not supply raw material for secondary manufacturing till 2008. In 2008, Genemedix claimed for return of the Lyophilizer and USD 8,646,705 for commercial usage of Lyophilizer

during last 6 years. The Company denied all the claims and filed a counter claim on July 14, 2008 claiming damages of USD 12,176,423 for loss of production during the installation and dismantling of machinery. The case is pending before the Sole Arbitrator Sri Justice B.P. Jeevan Reddy. Based on internal assessment and / or advice from legal counsellors the management is confident that no provision is required to be made for the above contingent liabilities as at March 31, 2014.

 

FIXED ASSETS:

 

Tangible assets

 

  • Land
  • Buildings
  • Plant and Machinery
  • Furniture and Fixtures
  • Office Equipment
  • Vehicles
  • Computer equipments

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                                       None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.64.78

UK Pound

1

Rs.99.54

Euro

1

Rs.73.08

 

 

INFORMATION DETAILS

 

Information Gathered by :

PRT 

 

 

Analysis Done by :

KAR

 

 

Report Prepared by :

SANS


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

8

PAID-UP CAPITAL

1~10

7

OPERATING SCALE

1~10

8

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

8

--PROFITABILITY

1~10

7

--LIQUIDITY

1~10

8

--LEVERAGE

1~10

7

--RESERVES

1~10

8

--CREDIT LINES

1~10

7

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

68

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.